目的 觀察燈銀腦通膠囊聯(lián)合依達(dá)拉奉注射液治療急性腦梗死的臨床療效。方法 選取2018年1月—2020年6月河南省精神病醫(yī)院收治的93例急性腦梗死患者為研究對(duì)象，按照入院奇偶順序法將所有患者分為對(duì)照組（46例）和治療組（47例）。對(duì)照組靜脈滴注依達(dá)拉奉注射液，將30 mg依達(dá)拉奉溶于100 mL 0.9%氯化鈉注射液中，30 min內(nèi)滴完，1次/d。治療組在對(duì)照組治療的基礎(chǔ)上口服燈銀腦通膠囊，2粒/次，3次/d。兩組患者均連續(xù)治療2周。觀察兩組臨床療效，比較兩組的美國(guó)國(guó)立衛(wèi)生院卒中量表（NIHSS）評(píng)分、Barthel指數(shù)評(píng)分量表（ADL）評(píng)分、環(huán)磷酸腺苷、血管內(nèi)皮細(xì)胞生長(zhǎng)因子（VEGF）、人纖溶酶原、β-內(nèi)啡肽水平變化。結(jié)果 治療后，治療組的總有效率87.23%高于對(duì)照組69.57%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組NIHSS評(píng)分降低，ADL評(píng)分升高（P<0.05），且治療組患者NIHSS評(píng)分低于對(duì)照組，ADL評(píng)分高于對(duì)照組（P<0.05）。治療后，兩組環(huán)磷酸腺苷、人纖溶酶原水平升高，VEGF、β-內(nèi)啡肽水平下降（P<0.05），且治療組環(huán)磷酸腺苷、人纖溶酶原水平高于對(duì)照組，VEGF、β-內(nèi)啡肽水平低于對(duì)照組（P<0.05）。結(jié)論 燈銀腦通膠囊聯(lián)合依達(dá)拉奉注射液治療急性腦梗死可有效減輕神經(jīng)損傷，提高生活自理能力，調(diào)節(jié)環(huán)磷酸腺苷、人纖溶酶原、VEGF、β-內(nèi)啡肽水平。

Objective To observe the clinical efficacy of Dengyin Naotong Capsules combined with Edaravone Injection in treatment of acute cerebral infarction.Methods Patients (93 cases) with acute cerebral infarction in Henan Psychiatric Hospital from January 2018 to June 2020 were randomly divided into the control group (46 cases) and the treatment group (47 cases). Patients in the control group were iv administered with Edaravone Injection, 30 mg added into 0.9% sodium chloride injection 100 mL, 30 min infusion completed, once daily. Patients in the treatment group were po administered with Dengyin Naotong Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and NIHSS scores, ADL scores, the levels of cyclic adenosine monophosphate, VEGF, human plasminogen, and β-endorphin in two group were compared.Results After treatment, the total effective rate of the treatment group (87.23%) was higher than 69.57% of the control group, and the difference was statistically significant (P<0.05). After treatment, the NIHSS scores in two groups were decreased, but the ADL scores in two groups were increased (P<0.05). And the NIHSS score in the treatment group was lower than that in the control group, but the ADL score in the treatment group was higher than that in the control group After treatment, the levels of adenosine cyclophosphate and human plasminogen in two groups were increased, but the levels of VEGF and β-endorphin in two groups were decreased (P<0.05). And the levels of adenosine cyclophosphate and human plasminogen in the treatment group were higher than that of the control group, but the levels of VEGF and β-endorphin in the treatment group were lower than that of the control group (P<0.05).Conclusion Dengyin Naotong Capsules combined with Edaravone Injection in treatment of acute cerebral infarction can effectively reduce nerve injury, improve self-care ability, and regulate the levels of cyclic adenosine monophosphate, human plasminogen, VEGF, and β-endorphin.

R971

河南省精神心理疾病臨床醫(yī)學(xué)研究中心開(kāi)放課題（2020-zxkfkt-008）